We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Sensitivity of White Blood Cell DNA to Damage from UV Light Distinguishes Cancer Patients from Healthy Individuals

By LabMedica International staff writers
Posted on 13 Aug 2014
A simple test that measures the extent of damage to white blood cell DNA caused by exposure to ultraviolet light has the potential to detect individuals with cancer before the appearance of any detectable symptoms.

Investigators at the University of Bradford (United Kingdom) recently described the Lymphocyte Genome Sensitivity (LGS) test that they had developed. More...
This test, which is based on "comet assay" technology, evaluates the damage caused to white blood cell DNA by exposure to different intensities of ultraviolet light (UVA).

The comet assay (single-cell gel electrophoresis) is a simple method for measuring DNA strand breaks in eukaryotic cells. Cells embedded in agarose on a microscope slide are dissolved with detergent and a high salt concentration to form nucleoids containing supercoiled loops of DNA linked to the nuclear matrix. Electrophoresis under alkaline conditions results in structures resembling comets, observed by fluorescence microscopy, with the intensity of the comet tail relative to the head reflecting the number of DNA breaks. Determine of the extent of DNA damage is obtained from visual analysis after DNA staining and calculation of fluorescence, which can be performed by manual scoring or automatically by imaging software.

For their study, the investigators looked at lymphocyte responses from 208 individuals: 20 with melanoma, 34 with colon cancer, four with lung cancer, 18 with suspected melanoma, 28 with polyposis, 10 with COPD (chronic obstructive pulmonary disease), and 94 healthy volunteers. Random and anonymous white blood cell samples were exposed to UVA light through five different depths of agar and then analyzed by the comet assay.

Results revealed that damage to DNA in white blood cells from cancer patients reached a stable plateau after treatment with different UVA intensities. In contrast the response of white blood cells from healthy individuals returned to control values.

Dr. Diana Anderson, professor of life sciences at the University of Bradford, said, “White blood cells are part of the body’s natural defense system. We know that they are under stress when they are fighting cancer or other diseases, so I wondered whether anything measurable could be seen if we put them under further stress with UVA light. We found that people with cancer have DNA which is more easily damaged by ultraviolet light than other people, so the test shows the sensitivity to damage of all the DNA—the genome—in a cell.”

“These are early results completed on three different types of cancer, and we accept that more research needs to be done; but these results so far are remarkable,” said Dr. Anderson. "Whilst the numbers of people we tested are, in epidemiological terms, quite small, in molecular epidemiological terms, the results are powerful. We have identified significant differences between the healthy volunteers, suspected cancer patients, and confirmed cancer patients of mixed ages at a statistically significant level. We believe that this confirms the test’s potential as a diagnostic tool.”

The study was published in the July 25, 2014, online edition of FASEB Journal.

Related Links:
University of Bradford



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Hematology Consumables
Bioblood Devices
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.